PMID- 35737252
OWN - NLM
STAT- MEDLINE
DCOM- 20220802
LR  - 20220808
IS  - 1573-7276 (Electronic)
IS  - 0262-0898 (Print)
IS  - 0262-0898 (Linking)
VI  - 39
IP  - 4
DP  - 2022 Aug
TI  - Intraperitoneal drug delivery systems releasing cytostatic agents to target 
      gastro-intestinal peritoneal metastases in laboratory animals: a systematic 
      review.
PG  - 541-579
LID - 10.1007/s10585-022-10173-8 [doi]
AB  - For peritoneal metastases (PM), there are few curative treatment options, and 
      they are only available for a select patient group. Recently, new therapies have 
      been developed to deliver intraperitoneal chemotherapy for a prolonged period, 
      suitable for a larger patient group. These drug delivery systems (DDSs) seem 
      promising in the experimental setting. Many types of DDSs have been explored in a 
      variety of animal models, using different cytostatics. This review aimed to 
      provide an overview of animal studies using DDSs containing cytostatics for the 
      treatment of gastro-intestinal PM and identify the most promising therapeutic 
      combinations. The review was conducted following the Preferred Reporting Items 
      for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and Systematic 
      Review Center for Laboratory Animal Experimentation (SYRCLE) guidelines. The 35 
      studies included revealed similar results: using a cytostatic-loaded DDS to treat 
      PM resulted in a higher median survival time (MST) and a lower intraperitoneal 
      tumor load compared to no treatment or treatment with a 'free' cytostatic or an 
      unloaded DDS. In 65% of the studies, the MST was significantly longer and in 24% 
      the tumor load was significantly lower in the animals treated with 
      cytostatic-loaded DDS. The large variety of experimental setups made it 
      impossible to identify the most promising DDS-cytostatic combination. In most 
      studies, the risk of bias was unclear due to poor reporting. Future studies 
      should focus more on improving the clinical relevance of the experiments, 
      standardizing the experimental study setup, and improving their methodological 
      quality and reporting.
CI  - (c) 2022. The Author(s).
FAU - Wintjens, Anne G W E
AU  - Wintjens AGWE
AD  - NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht 
      University, Maastricht, The Netherlands. a.wintjens@maastrichtuniversity.nl.
AD  - Department of Surgery, Maastricht University Medical Centre, PO Box 616, 6200 MD, 
      Maastricht, The Netherlands. a.wintjens@maastrichtuniversity.nl.
FAU - Simkens, Geert A
AU  - Simkens GA
AD  - Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
FAU - Fransen, Peter-Paul K H
AU  - Fransen PKH
AD  - UPyTher BV, Eindhoven, The Netherlands.
FAU - Serafras, Narcis
AU  - Serafras N
AD  - Department of Surgery, Maastricht University Medical Centre, PO Box 616, 6200 MD, 
      Maastricht, The Netherlands.
FAU - Lenaerts, Kaatje
AU  - Lenaerts K
AD  - NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht 
      University, Maastricht, The Netherlands.
AD  - Department of Surgery, Maastricht University Medical Centre, PO Box 616, 6200 MD, 
      Maastricht, The Netherlands.
FAU - Franssen, Gregor H L M
AU  - Franssen GHLM
AD  - Department of Education, Content & Support, University Library, Maastricht 
      University, Maastricht, The Netherlands.
FAU - de Hingh, Ignace H J T
AU  - de Hingh IHJT
AD  - Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
AD  - GROW School for Oncology and Developmental Biology, Maastricht University, 
      Maastricht, The Netherlands.
FAU - Dankers, Patricia Y W
AU  - Dankers PYW
AD  - Institute for Complex Molecular Systems, Eindhoven University of Technology, 
      Eindhoven, The Netherlands.
AD  - Department of Biomedical Engineering, Laboratory of Chemical Biology, Eindhoven 
      University of Technology, Eindhoven, The Netherlands.
FAU - Bouvy, Nicole D
AU  - Bouvy ND
AD  - Department of Surgery, Maastricht University Medical Centre, PO Box 616, 6200 MD, 
      Maastricht, The Netherlands.
AD  - GROW School for Oncology and Developmental Biology, Maastricht University, 
      Maastricht, The Netherlands.
FAU - Peeters, Andrea
AU  - Peeters A
AD  - Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht 
      University Medical Centre, Maastricht, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20220623
PL  - Netherlands
TA  - Clin Exp Metastasis
JT  - Clinical & experimental metastasis
JID - 8409970
RN  - 0 (Cytostatic Agents)
SB  - IM
CIN - Clin Exp Metastasis. 2022 Aug 2;:. PMID: 35917063
MH  - Animals
MH  - *Cytostatic Agents/therapeutic use
MH  - Drug Delivery Systems
MH  - *Gastrointestinal Neoplasms/drug therapy
MH  - *Peritoneal Neoplasms/secondary
MH  - Peritoneum
PMC - PMC9338897
OTO - NOTNLM
OT  - Animal experiments
OT  - Drug delivery systems
OT  - Intraperitoneal chemotherapy
OT  - Peritoneal metastases
OT  - Systematic review
EDAT- 2022/06/24 06:00
MHDA- 2022/08/03 06:00
PMCR- 2022/06/23
CRDT- 2022/06/23 11:21
PHST- 2022/02/18 00:00 [received]
PHST- 2022/05/31 00:00 [accepted]
PHST- 2022/06/24 06:00 [pubmed]
PHST- 2022/08/03 06:00 [medline]
PHST- 2022/06/23 11:21 [entrez]
PHST- 2022/06/23 00:00 [pmc-release]
AID - 10.1007/s10585-022-10173-8 [pii]
AID - 10173 [pii]
AID - 10.1007/s10585-022-10173-8 [doi]
PST - ppublish
SO  - Clin Exp Metastasis. 2022 Aug;39(4):541-579. doi: 10.1007/s10585-022-10173-8. 
      Epub 2022 Jun 23.